Styczeń Krzysztof, Siwek Marcin, Sowa-Kućma Magdalena, Dudek Dominika, Reczyński Witold, Szewczyk Bernadeta, Misztak Paulina, Topór-Mądry Roman, Opoka Włodzimierz, Nowak Gabriel
Zakład Zaburzeń Afektywnych Katedry Psychiatrii UJ CM.
Pracownia Neurobiologii Pierwiastków Śladowych Instytutu Farmakologii PAN w Krakowie.
Psychiatr Pol. 2015;49(6):1265-76. doi: 10.12740/PP/OnlineFirst/44137.
The growing body of evidence suggests that magnesium levels can serve as a marker of major depressive disorder (MDD), but findings from clinical trials remain inconclusive. The aim of the presented study was to determine the magnesium concentration in serum of patients with MDD (in the active stage of the disease or in remission) and to analyze the role of magnesium levels as apotential marker of the disease.
Sixty-nine patients with current depressive episode, 45 patients in remission and 50 healthy volunteers were enrolled into the case-control study. The magnesium concentration was measured by flame atomic absorption spectrometry (FAAS).
The mean serum magnesium concentration of patients in the depressed phase was significantly higher, compared to the control group. Moreover, magnesium levels of patients in the remission were not significantly different from the concentrations recorded in the healthy volunteers. There was also a positive correlation between the magnesium levels and the severity of depression measured by the Hamilton Rating Scale for Depression (HDRS) and the Montgomery-Asberg Depression Rating Scale (MADRS).
The obtained results may suggest a role of magnesium as a state marker reflecting the pathophysiological changes underlying MDD and accompanying severe depressive episodes.
越来越多的证据表明，镁水平可作为重度抑郁症（MDD）的一个标志物，但临床试验的结果仍无定论。本研究的目的是测定MDD患者（疾病活动期或缓解期）血清中的镁浓度，并分析镁水平作为该疾病潜在标志物的作用。
69例当前有抑郁发作的患者、45例缓解期患者和50名健康志愿者被纳入病例对照研究。通过火焰原子吸收光谱法（FAAS）测定镁浓度。
与对照组相比，抑郁期患者的平均血清镁浓度显著更高。此外，缓解期患者的镁水平与健康志愿者的记录浓度无显著差异。镁水平与通过汉密尔顿抑郁评定量表（HDRS）和蒙哥马利-阿斯伯格抑郁评定量表（MADRS）测量的抑郁严重程度之间也存在正相关。
所获得的结果可能表明镁作为一种状态标志物反映了MDD及伴随的重度抑郁发作背后的病理生理变化。
